Lianghe Lu

1.1k total citations
41 papers, 634 citations indexed

About

Lianghe Lu is a scholar working on Hepatology, Cancer Research and Oncology. According to data from OpenAlex, Lianghe Lu has authored 41 papers receiving a total of 634 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Hepatology, 17 papers in Cancer Research and 15 papers in Oncology. Recurrent topics in Lianghe Lu's work include Hepatocellular Carcinoma Treatment and Prognosis (28 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (12 papers) and Cancer, Lipids, and Metabolism (11 papers). Lianghe Lu is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (28 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (12 papers) and Cancer, Lipids, and Metabolism (11 papers). Lianghe Lu collaborates with scholars based in China, Taiwan and Hong Kong. Lianghe Lu's co-authors include Rong Guo, Shaohua Li, Wei Wei, Jie Mei, Yihong Ling, Jingwen Zou, Wen‐Ping Lin, Chong Zhong, Minshan Chen and Lie Zheng and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Biochemical and Biophysical Research Communications.

In The Last Decade

Lianghe Lu

38 papers receiving 630 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lianghe Lu China	17	365	240	155	151	144	41	634
Diyang Xie China	8	436 1.2×	150 0.6×	150 1.0×	149 1.0×	215 1.5×	10	632
Guoliang Shao China	9	375 1.0×	155 0.6×	86 0.6×	87 0.6×	134 0.9×	34	553
Yong‐Fa Zhang China	17	397 1.1×	160 0.7×	174 1.1×	170 1.1×	194 1.3×	32	654
Jie Mei China	18	525 1.4×	263 1.1×	243 1.6×	211 1.4×	212 1.5×	51	898
Osakuni Morimoto Japan	11	484 1.3×	190 0.8×	161 1.0×	203 1.3×	288 2.0×	44	738
Vikki Tang China	8	564 1.5×	183 0.8×	109 0.7×	197 1.3×	311 2.2×	20	711
M. Giovanelli Italy	8	543 1.5×	159 0.7×	173 1.1×	287 1.9×	293 2.0×	11	825
Tatsuya Orimo Japan	13	279 0.8×	243 1.0×	156 1.0×	313 2.1×	139 1.0×	79	684
Yong Le China	10	464 1.3×	131 0.5×	128 0.8×	189 1.3×	136 0.9×	11	652

Countries citing papers authored by Lianghe Lu

Since Specialization

Citations

This map shows the geographic impact of Lianghe Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lianghe Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lianghe Lu more than expected).

Fields of papers citing papers by Lianghe Lu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lianghe Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lianghe Lu. The network helps show where Lianghe Lu may publish in the future.

Co-authorship network of co-authors of Lianghe Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Lianghe Lu. A scholar is included among the top collaborators of Lianghe Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lianghe Lu. Lianghe Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yuan, Shasha, Cheng Zhang, Fan Zhou, et al.. (2025). Refining risk stratification in hepatocellular carcinoma by integrating tertiary lymphoid structures and microvascular invasion: a multicenter retrospective study. International Journal of Surgery. 111(11). 8212–8225.

Deng, Min, et al.. (2025). Transarterial chemoembolization versus hepatic arterial infusion chemotherapy as first treatment for hepatocellular carcinoma with macrovascular invasion. International Journal of Medical Sciences. 22(6). 1415–1424.

Lu, Lianghe, Jie Mei, Yihong Ling, et al.. (2024). Hepatic Arterial Infusion Chemotherapy vs Transcatheter Arterial Chemoembolization as Adjuvant Therapy Following Surgery for MVI-Positive Hepatocellular Carcinoma: A Multicenter Propensity Score Matching Analysis. Journal of Hepatocellular Carcinoma. Volume 11. 665–678. 4 indexed citations

Li, Shaohua, Jie Mei, Rongce Zhao, et al.. (2024). Comparing PD-L1 with PD-1 antibodies combined with lenvatinib and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma. Frontiers in Immunology. 15. 1491857–1491857. 2 indexed citations

Jin, Xiaohan, Jin‐Ling Duan, Miaomiao Dai, et al.. (2024). METTL3 confers oxaliplatin resistance through the activation of G6PD-enhanced pentose phosphate pathway in hepatocellular carcinoma. Cell Death and Differentiation. 32(3). 466–479. 14 indexed citations

Wen, Yuhua, Shaohua Li, Zhijun Geng, et al.. (2024). Imaging-based surrogate classification for risk stratification of hepatocellular carcinoma with microvascular invasion to adjuvant hepatic arterial infusion chemotherapy: a multicenter retrospective study. International Journal of Surgery. 111(1). 872–883. 4 indexed citations

Nie, Run‐Cong, et al.. (2023). Association between Early Immune-Related Adverse Events and Survival in Patients Treated with PD-1/PD-L1 Inhibitors. Journal of Clinical Medicine. 12(3). 736–736. 12 indexed citations

Lin, Wenping, Lianghe Lu, Rongliang Zheng, et al.. (2023). Vessels encapsulating tumor clusters: a novel efficacy predictor of hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology. 149(19). 17231–17239. 6 indexed citations

Li, Shaohua, Jie Mei, Qiaoxuan Wang, et al.. (2023). Comparison of anti–PD-L1 with anti–PD-1 antibodies in the combination of HAIC and lenvatinib for the treatment of unresectable hepatocellular carcinoma.. Journal of Clinical Oncology. 41(4_suppl). 509–509. 2 indexed citations

10.

Chen, Jierong, et al.. (2022). Body mass index, as a novel predictor of hepatocellular carcinoma patients treated with Anti-PD-1 immunotherapy. Frontiers in Medicine. 9. 981001–981001. 6 indexed citations

11.

Lu, Lianghe, Zhangping He, Run‐Cong Nie, et al.. (2022). C-Reactive Protein Levels Predict Responses to PD-1 Inhibitors in Hepatocellular Carcinoma Patients. Frontiers in Immunology. 13. 808101–808101. 29 indexed citations

12.

Lu, Lianghe, Wei Wei, Shaohua Li, et al.. (2021). A new horizon in risk stratification of hepatocellular carcinoma by integrating vessels that encapsulate tumor clusters and microvascular invasion. Hepatology International. 15(3). 651–662. 27 indexed citations

13.

Li, Shaohua, Jie Mei, Qiaoxuan Wang, et al.. (2021). Transarterial infusion chemotherapy with FOLFOX for advanced hepatocellular carcinoma: a multi-center propensity score matched analysis of real-world practice. HepatoBiliary Surgery and Nutrition. 10(5). 631–645. 15 indexed citations

14.

Zhang, Yong‐Fa, Lianghe Lu, Chong Zhong, et al.. (2021). Prognostic Value of the Preoperative Lymphocyte-C-Reactive Protein Ratio in Hepatocellular Carcinoma Patients Treated with Curative Intent: A Large-Scale Multicentre Study. Journal of Inflammation Research. Volume 14. 2483–2495. 13 indexed citations

15.

Lu, Lianghe, Wei Wei, Yihong Ling, et al.. (2021). Immune‐related adverse events predict responses to PD‐1 blockade immunotherapy in hepatocellular carcinoma. International Journal of Cancer. 149(4). 959–966. 16 indexed citations

16.

Lu, Lianghe, Wei Wei, Shaohua Li, Yongfa Zhang, & Rong Guo. (2021). The lymphocyte-C-reactive protein ratio as the optimal inflammation-based score in patients with hepatocellular carcinoma underwent TACE. Aging. 13(4). 5358–5368. 24 indexed citations

17.

Mei, Jie, Shaohua Li, QiJiong Li, et al.. (2021). Anti-PD-1 Immunotherapy Improves the Efficacy of Hepatic Artery Infusion Chemotherapy in Advanced Hepatocellular Carcinoma. SHILAP Revista de lepidopterología. Volume 8. 167–176. 44 indexed citations

18.

Lu, Lianghe, et al.. (2020). A Novel Prognostic Nomogram for Patients With Recurrence of Intrahepatic Cholangiocarcinoma After Initial Surgery. Frontiers in Oncology. 10. 434–434. 11 indexed citations

19.

Huang, Xin, Chaobin He, Guo‐He Lin, et al.. (2020). Induced CD10 expression during monocyte-to-macrophage differentiation identifies a unique subset of macrophages in pancreatic ductal adenocarcinoma. Biochemical and Biophysical Research Communications. 524(4). 1064–1071. 19 indexed citations

20.

Li, Shaohua, Jie Mei, Qiaoxuan Wang, et al.. (2020). Postoperative Adjuvant Transarterial Infusion Chemotherapy with FOLFOX Could Improve Outcomes of Hepatocellular Carcinoma Patients with Microvascular Invasion: A Preliminary Report of a Phase III, Randomized Controlled Clinical Trial. Annals of Surgical Oncology. 27(13). 5183–5190. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact